GLAUKOS Corp(GKOS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,100 of 2,960 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
GKOS Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for GLAUKOS Corp (GKOS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GKOS at 40.5/100 on a 32-signal composite quality model, placing it at rank #2,100 of 2,960 stocks — the bottom half of the AI-ranked universe. GKOS scores in the top quartile across revenue growth (89.3). Areas of concern include balance sheet strength (11.2) and profitability (12.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 13.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), GLAUKOS Corp reports quarterly revenue of $185.6M, net income of $-18.4M, free cash flow of $12.1M. Top institutional holders of GKOS by reported 13-F value include BlackRock, Jupiter Topco, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. GKOS trades on the NYSE exchange and files with the SEC under CIK 1192448. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GKOS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GLAUKOS Corp directly from SEC EDGAR. GLAUKOS Corp's 13F Pro composite quality score has ranged between 21 and 41 since 2021, currently 40.5 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$185.6M
Net Income
Q2 2026
$-18.4M
Free Cash Flow
Q2 2026
$12.1M
ROIC
Q2 2026
-10.1%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+32.3% YoYNet Income
-28.2% YoYOperating Income
-63.1% YoYEPS (Diluted)
-18.4% YoYTotal Assets
-8.3% YoYOp. Cash Flow
+75.9% YoYFree Cash Flow
+66.8% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $507.4M +32.3% | $383.5M +21.9% | $314.7M +11.3% | $282.9M -3.8% | $294.0M +30.7% | $225.0M |
| Net Income | $-187.7M -28.2% | $-146.4M -8.7% | $-134.7M -35.8% | $-99.2M -100.0% | $-49.6M +58.8% | $-120.3M |
| Operating Income | $-199.6M -63.1% | $-122.4M +4.9% | $-128.7M -56.4% | $-82.3M -150.4% | $-32.9M +73.4% | $-123.6M |
| EPS (Diluted) | $-3.28 -18.4% | $-2.77 +0.4% | $-2.78 -33.0% | $-2.09 -95.3% | $-1.07 +60.4% | $-2.70 |
| Total Assets | $893.5M -8.3% | $974.8M +3.7% | $940.4M -6.2% | $1.00B -4.5% | $1.05B +4.4% | $1.01B |
| Operating Cash Flow | $-14.8M +75.9% | $-61.3M -6.2% | $-57.8M -74.6% | $-33.1M -233.9% | $24.7M +207.5% | $-23.0M |
| Free Cash Flow | $-22.5M +66.8% | $-67.6M +13.3% | $-78.0M -23.1% | $-63.3M -174.5% | $-23.1M +22.9% | $-29.9M |
Get alerted when GKOS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for GLAUKOS Corp including:
Top Institutional Holders of GKOS
BlackRock, Inc.
$1.3B9,540,056 shJupiter Topco LLC
$679.6M4,862,894 shVANGUARD PORTFOLIO MANAGEMENT LLC
$464.3M3,321,839 shPRIMECAP MANAGEMENT CO/CA/
$425.0M3,040,705 shVANGUARD CAPITAL MANAGEMENT LLC
$356.5M2,551,132 shSTATE STREET CORP
$323.7M2,315,568 shMILLENNIUM MANAGEMENT LLC
$221.0M1,581,016 shHolocene Advisors, LP
$211.7M1,514,931 shGEODE CAPITAL MANAGEMENT, LLC
$204.6M1,463,448 shCITADEL ADVISORS LLC
$194.3M1,390,017 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $1.3B | 9,540,056 |
| Jupiter Topco LLC | $679.6M | 4,862,894 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $464.3M | 3,321,839 |
| PRIMECAP MANAGEMENT CO/CA/ | $425.0M | 3,040,705 |
| VANGUARD CAPITAL MANAGEMENT LLC | $356.5M | 2,551,132 |
| STATE STREET CORP | $323.7M | 2,315,568 |
| MILLENNIUM MANAGEMENT LLC | $221.0M | 1,581,016 |
| Holocene Advisors, LP | $211.7M | 1,514,931 |
| GEODE CAPITAL MANAGEMENT, LLC | $204.6M | 1,463,448 |
| CITADEL ADVISORS LLC | $194.3M | 1,390,017 |
Companies Similar to GKOS
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
ARROWHEAD PHARMACEUTICALS, INC.
INSMED Inc
Adaptive Biotechnologies Corp
RHYTHM PHARMACEUTICALS, INC.
MADRIGAL PHARMACEUTICALS, INC.
Axogen, Inc.
Guardant Health, Inc.
Axsome Therapeutics, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put GKOS on your watchlist
Track score changes the day GLAUKOS Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is GKOS a good stock to buy?
13F Pro's AI-powered analysis of GLAUKOS Corp (GKOS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GKOS are available on the GKOS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. GKOS is classified as a large company.
Which hedge funds own GKOS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GKOS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of GLAUKOS Corp's investment landscape.